Premium
The development, evidence, and current use of ATX‐101 for the treatment of submental fat
Author(s) -
Georgesen Corey,
Lipner Shari R.
Publication year - 2017
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.12347
Subject(s) - deoxycholic acid , pharmacodynamics , pharmacokinetics , medicine , pharmacology , adverse effect , clinical trial , bile acid
Summary ATX‐101 (deoxycholic acid) is the first pharmaceutical therapy approved by the FDA for the reduction in submental fat. Deoxycholic acid is an endogenous secondary bile acid that normally solubilizes dietary fat, contributing to its breakdown and absorption within the gut. This article reviews the identification of deoxycholic acid as a lipolytic agent, and the mechanism of action, pharmacokinetics, and pharmacodynamics of ATX‐101. In addition to phase I/II trials, four Phase III clinical trials have evaluated safety and efficacy of ATX‐101. These studies helped establish the appropriate dosage, administration techniques, warnings, and side effects of ATX‐101. ATX‐101 is effective in treating submental fat. Adverse events, although common, are mild and transient.